title: Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica.
abstract: Recently, a consensus International Prognostic Scoring System (IPSS) for predicting outcome and planning therapy in the myelodysplastic syndromes (MDS) has been developed. However, the intermediate-risk cytogenetic subgroup defined by the IPSS includes a miscellaneous number of different single abnormalities for which real prognosis at present is uncertain. The main aims of this study were to evaluate in an independent series the prognostic value of the IPSS and to identify chromosomal abnormalities with a previously unrecognized good or poor prognosis in 640 patients. In univariate analyses, cases with single 1q abnormalities experienced poor survival, whereas those with trisomy 8 had a higher risk of acute leukaemic transformation than the remaining patients (P = 0.004 and P = 0.009 respectively). Patients with single del(12p) had a similar survival to patients with a normal karyotype and showed some trend for a better survival than other cases belonging to the IPSS intermediate-risk cytogenetic subgroup (P = 0.045). Multivariate analyses demonstrated that IPSS cytogenetic prognostic subgroup, proportion of bone marrow blasts and haemoglobin level were the main prognostic factors for survival, and the first two characteristics and platelet count were the best predictors of acute leukaemic transformation risk. A large international co-operative study should be carried out to clarify these findings.
authors.affiliation: Hospital de l'Esperança/Hospital del Mar/Hospital Central l'Aliança (Barcelona), Hospital la Fé (Valencia), Spain. E0037@imas.imim.es
authors.forename: F
authors.initials: F
authors.lastname: Solé
authors.forename: B
authors.initials: B
authors.lastname: Espinet
authors.forename: G F
authors.initials: GF
authors.lastname: Sanz
authors.forename: J
authors.initials: J
authors.lastname: Cervera
authors.forename: M J
authors.initials: MJ
authors.lastname: Calasanz
authors.forename: E
authors.initials: E
authors.lastname: Luño
authors.forename: F
authors.initials: F
authors.lastname: Prieto
authors.forename: I
authors.initials: I
authors.lastname: Granada
authors.forename: J M
authors.initials: JM
authors.lastname: Hernández
authors.forename: J C
authors.initials: JC
authors.lastname: Cigudosa
authors.forename: J L
authors.initials: JL
authors.lastname: Diez
authors.forename: E
authors.initials: E
authors.lastname: Bureo
authors.forename: M L
authors.initials: ML
authors.lastname: Marqués
authors.forename: E
authors.initials: E
authors.lastname: Arranz
authors.forename: R
authors.initials: R
authors.lastname: Ríos
authors.forename: J A
authors.initials: JA
authors.lastname: Martínez Climent
authors.forename: T
authors.initials: T
authors.lastname: Vallespí
authors.forename: L
authors.initials: L
authors.lastname: Florensa
authors.forename: S
authors.initials: S
authors.lastname: Woessner
mesh_terms: D000328:Adult; D000368:Aged; D002471:Cell Transformation, Neoplastic; D002869:Chromosome Aberrations; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments; D015994:Incidence; D007951:Leukemia, Myeloid / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D015996:Survival Rate
chemical_list: D007140:Immunoglobulin Fab Fragments